AMRX vs. CORT
AMRX (Amneal Pharmaceuticals, Inc.) and CORT (Corcept Therapeutics Incorporated) are both stocks. Both are in the Healthcare sector — AMRX in Drug Manufacturers - Specialty & Generic, CORT in Biotechnology. Over the past 10 years, AMRX returned -5.79%/yr vs 31.34%/yr for CORT. At a 0.24 correlation, their price movements are largely independent.
Performance
AMRX vs. CORT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AMRX achieves a 27.86% return, which is significantly lower than CORT's 129.05% return. Over the past 10 years, AMRX has underperformed CORT with an annualized return of -5.79%, while CORT has yielded a comparatively higher 31.34% annualized return.
AMRX
- 1D
- -0.62%
- 1M
- 29.71%
- YTD
- 27.86%
- 6M
- 25.66%
- 1Y
- 106.01%
- 3Y*
- 77.51%
- 5Y*
- 25.09%
- 10Y*
- -5.79%
CORT
- 1D
- -0.25%
- 1M
- 32.36%
- YTD
- 129.05%
- 6M
- -6.34%
- 1Y
- 11.67%
- 3Y*
- 53.92%
- 5Y*
- 29.06%
- 10Y*
- 31.34%
AMRX vs. CORT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AMRX Amneal Pharmaceuticals, Inc. | 27.86% | 59.09% | 30.48% | 205.03% | -58.46% | 4.81% | -5.19% | -64.38% | -18.74% | 25.66% |
CORT Corcept Therapeutics Incorporated | 129.05% | -30.94% | 55.14% | 59.92% | 2.58% | -24.31% | 116.20% | -9.43% | -26.02% | 148.76% |
Correlation
The correlation between AMRX and CORT is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jan 15, 2009 | 0.24 |
Fundamentals
AMRX:
$5.30B
CORT:
$8.32B
AMRX:
$0.38
CORT:
$0.41
AMRX:
42.82
CORT:
194.37
AMRX:
1.49
CORT:
96.82
AMRX:
1.72
CORT:
12.03
AMRX:
6.90
CORT:
13.05
AMRX:
$3.05B
CORT:
$769.10M
AMRX:
$1.18B
CORT:
$755.64M
AMRX:
$626.02M
CORT:
$3.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AMRX vs. CORT — Risk / Return Rank
AMRX
CORT
AMRX vs. CORT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AMRX | CORT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.16 | ||
| Sortino ratioReturn per unit of downside risk | +3.25 | ||
| Omega ratioGain probability vs. loss probability | 1.50 | 1.16 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 4.79 | 0.18 | +4.61 |
| Martin ratioReturn relative to average drawdown | 11.85 | 0.33 | +11.52 |
Loading charts...
Drawdowns
AMRX vs. CORT - Drawdown Comparison
The maximum AMRX drawdown since its inception was -97.52%, roughly equal to the maximum CORT drawdown of -94.29%. Use the drawdown chart below to compare losses from any high point for AMRX and CORT.
Loading charts...
Drawdown Indicators
| AMRX | CORT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.52% | -94.29% | -3.23% |
Max Drawdown (1Y)Largest decline over 1 year | -22.25% | -64.40% | +42.15% |
Max Drawdown (3Y)Largest decline over 3 years | -26.80% | -71.85% | +45.05% |
Max Drawdown (5Y)Largest decline over 5 years | -78.29% | -71.85% | -6.44% |
Max Drawdown (10Y)Largest decline over 10 years | -95.98% | -71.85% | -24.13% |
Current DrawdownCurrent decline from peak | -68.60% | -30.21% | -38.39% |
Average DrawdownAverage peak-to-trough decline | -54.34% | -53.43% | -0.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.98% | 35.39% | -26.41% |
Volatility
AMRX vs. CORT - Volatility Comparison
The current volatility for Amneal Pharmaceuticals, Inc. (AMRX) is 11.49%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 13.61%. This indicates that AMRX experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AMRX | CORT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.49% | 13.61% | -2.12% |
Volatility (6M)Calculated over the trailing 6-month period | 24.31% | 85.06% | -60.75% |
Volatility (1Y)Calculated over the trailing 1-year period | 32.20% | 77.18% | -44.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.98% | 74.59% | -23.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 65.26% | 67.22% | -1.96% |
Dividends
AMRX vs. CORT - Dividend Comparison
Neither AMRX nor CORT has paid dividends to shareholders.
Financials
AMRX vs. CORT - Financials Comparison
This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AMRX vs. CORT - Profitability Comparison
AMRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Amneal Pharmaceuticals, Inc. reported a gross profit of 320.11M and revenue of 722.52M. Therefore, the gross margin over that period was 44.3%.
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
AMRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Amneal Pharmaceuticals, Inc. reported an operating income of 133.54M and revenue of 722.52M, resulting in an operating margin of 18.5%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
AMRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Amneal Pharmaceuticals, Inc. reported a net income of 62.50M and revenue of 722.52M, resulting in a net margin of 8.7%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
Frequently Asked Questions
AMRX and CORT have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CORT has higher volatility (13.61%) compared to AMRX (11.49%). In terms of maximum drawdown, AMRX dropped -97.52% vs CORT's -94.29%.
AMRX currently has the higher Sharpe Ratio (3.32 vs 0.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AMRX and CORT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer